Sustained Release Pan-VEGFR Inhibitor Implant
AR-14034 SR (axitinib) is an investigational sustained release bioerodible implant administered by intravitreal injection that may provide therapeutic benefit to wAMD and DME patients for up to 12 months. It has not been approved by the U.S. Food and Drug Administration (FDA).
How AR-14034 SR is Thought to Work
VEGF is a protein that promotes the growth of new blood vessels. As an inhibitor of all VEGF receptors, AR-14034 (axitinib) provides pan-VEGF inhibition (blocks signaling by VEGF-A, B, C, and D) and therefore has the potential for greater efficacy than current products that inhibit only VEGF-B and/or VEGF-A). Approved by the FDA in 2012 for the treatment of renal cell carcinoma, axitinib has a higher potency and less off-target activity than other small molecule VEGF receptor inhibitors. To create the sustained release intravitreal implant, AR-14034 SR, Aerie has utilized a proprietary bioerodible polymer blend providing controlled release of axitinib to the back of the eye while avoiding microparticles that can migrate to front of the eye.
In laboratory and animal studies, the drug release rate predicts up to a 12 month-duration of efficacy, supporting the potential for once-a-year injection.1
In vitro: In Vivo Comparison
Aerie is currently pursuing investigational new drug application (IND)-enabling studies for AR-14034 SR and plans to file the IND and initiate human clinical trials in the second half of 2022.
- Data on file. Aerie Pharmaceuticals, Inc.